Filing Flows

Filing Flows › Biodesix (BDSX) › Next earnings date

Biodesix (BDSX) earnings: missed the estimate

Biodesix (BDSX) reported on Nov 5, 2026 and missed the EPS estimate: −$0.75 against −$0.75 (-0.2%). Revenue was $24.0M for Q3 2026, +10% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result−0.2% vs estimate
Beat rate80%

The last report

Biodesix reported revenue of $24.0M for the third quarter 2026 (+10% Y/Y), net loss $8.0M: Diagnostic Tests $23.1M, Development Services $986K. How it makes money → · Every quarter →

Biodesix: EPS against the estimate, last 5 reportsBiodesix: EPS against the estimate, last 5 reportsEstimateReported−$1.51−$1.16Nov 25−$0.87−$0.49Feb 26−$1.10−$0.81May 26−$0.90−$0.71Aug 26−$0.75−$0.75Nov 26
Latest (Nov 26): Estimate −$0.75, Reported −$0.75.

Biodesix's latest quarter

Biodesix, Q3 2026: revenue $24.0M (+10% year over year), operating margin -25.4%, net loss $8.0M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did Biodesix beat earnings?

Biodesix (BDSX) reported on Nov 5, 2026 and missed the EPS estimate: −$0.75 against −$0.75 (-0.2%).

When does BDSX report earnings?

The next date is not set yet.

Does Biodesix usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.